Not finding it? Sign in to also search OpenAlex live.
-
TGF-β and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).2021 Journal of Clinical Oncology conference-abstract Medicine Esophageal Cancer Research and Treatment
Linde M. Veen, Maarten C.C.M. Hulshof, Connie R. Jiménez, Edwin P. J. G. Cuppen, Laurens Victor Beerepoot, Geert‐Jan Creemers, +9 more
2citations -
89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.2020 Journal of Clinical Oncology conference-abstract Medicine Radiopharmaceutical Chemistry and Applications Open access
Sarah R. Verhoeff, Pim P. van de Donk, Erik H.J.G. Aarntzen, Iris H.C. Miedema, Sjoukje F. Oosting, Jens Voortman, +4 more
12citations -
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Hiddo Gort, T. Jeroen N. Hiltermann, +14 more
22citations -
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC2024 Cancer Research conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses
Willemijn S.M.E. Theelen, Maurice Pérol, Kristof Cuppens, Ingel Demedts, Frank Borm, Bonne Biesma, +17 more
3citations -
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.2026 Journal of Clinical Oncology conference-abstract Medicine Renal cell carcinoma treatment Open access
Robert John Motzer, Se Hoon Park, Ray McDermott, Camillo Porta, Daniel Yick Chin Heng, Mauricio Burotto, +12 more
8citations -
Abstract 1582: A pre-existing inflammatory immune microenvironment predicts the clinical and immunological response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 peptide vaccination
Ziena Abdulrahman, Noel F.C.C. de Miranda, Mariette I. van Poelgeest, Sjoerd H. van der Burg
0citations -
Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.2024 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Karlijn de Joode, Harry J.M. Groen, Michel M. van den Heuvel, Jeroen S. Kloover, Femke S. van der Meer, Cor H. van der Leest, +12 more
0citations -
The Pro-autoimmune allele of tyrosine phosphatase PTPN22 enhances anti-viral and anti-tumor immunity2020 The Journal of Immunology conference-abstract Biochemistry, Genetics and Molecular Biology Protein Tyrosine Phosphatases
Robin C. Orozco, Kristi Marquardt, Kerri A. Mowen, Isaraphorn Pratumchai, John Ross Teijaro, Linda A. Sherman
0citations -
Outcome prediction in resectable esophageal adenocarcinoma based on clinical variables, radiomics, and ctDNA.2023 Journal of Clinical Oncology conference-abstract Medicine Esophageal Cancer Research and Treatment Open access
Tom van den Ende, Steven C. Kuijper, Yousif Widaatalla, Wyanne A. Noortman, Floris H. P. van Velden, Henry C. Woodruff, +9 more
2citations -
75. PROGRAMMED DEATH RECEPTOR LIGAND ONE EXPRESSION MAY INDEPENDENTLY PREDICT SURVIVAL IN NON-SMALL CELL LUNG CARCINOMA BRAIN METASTASES PATIENTS RECEIVING IMMUNOTHERAPY2020 Neuro-Oncology Advances conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Alexander F. C. Hulsbergen, Marco Mammi, Steven Nagtegaal, Vasileios K. Kavouridis, Timothy Richard Smith, Bryan Iorgulescu, +4 more
0citations
21 results